Jocasta Neuroscience partners with Diamond Therapeutics on three non-hallucinogenic drug candidates
Jocasta Neuroscience and Diamond Therapeutics will evaluate three psychedelic-inspired 5-HT2A receptor compounds for cognitive impairment and neurodegeneration. The agreement gives Jocasta an option to license successful candidates, but the molecules have not yet demonstrated clinical efficacy or an absence of hallucinogenic effects in humans.